leadf
logo-loader
view4D pharma PLC
(
AIM:DDDDNASDAQ:LBPS
)

4D pharma to display two posters showcasing positive data for cancer asset at oncology conference

The new information will be provided at the European Society for Medical Oncology

4D pharma PLC -
MRx0518 is a new class of drug called a live biotherapeutic product (LBP), derived from the human microbiome, which is an ecosystem of bacteria found mainly in the gut

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it will display two poster presentations at an upcoming cancer conference providing biomarker data on its lead asset, MRx0518.

The first indicates the potential for the drug to overcome a form of acquired resistance to cancer treatment.

The second reveals the “potent activity” of orally administered MRx0518 directly on the human immune system.

Both posters will be showcased at the European Society for Medical Oncology (ESMO) Congress, starting Thursday (September 16). They will be on the company’s website from that date.

MRx0518 is a new class of drug called a live biotherapeutic product (LBP), derived from the microbiome, which is an ecosystem of bacteria found mainly in the human gut.

Delivered in a capsule taken by mouth, it stimulates the body's immune system, directing it to produce cytokines and cells that are known to attack tumours.

It is currently being evaluated in three clinical trials in cancer patients.

“At the core of 4D pharma's platform is the importance of understanding the impact of live biotherapeutics on human biology to rationally select and develop candidates, predict and measure response,” said the company’s chief scientific officer, Dr Alex Stevenson.

“These new biomarker data provide us with critical guidance on the biological and mechanistic impact of MRx0518 therapy in patients with various solid tumours.

"These new findings indicate the potential to predict patients most likely to respond to MRx0518 therapy based on tumour biology."

For more information on the posters click here

Quick facts: 4D pharma PLC

Follow
AIM:DDDD

Price: 64 GBX

Market Cap: £115.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE rides on wave of results and reopening optimism boosts the market mood

FTSE 100 rose as a wave of results and reopening optimism boosted the mood on investors. Anglo American and Shell were good, BT not so much and the blue-chip index was up 45 at points at 7,061. Lloyds Banking Group (LSE:LLOY) PLC declared its first interim dividend after the recent removal of...

on 29/7/21

2 min read